Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsGlenmarkpharma

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Go long in Glenmark Pharma, says Gaurav Bissa

      Gaurav Bissa, Derivatives Analyst at LKP Securities is of the view that one may go long in Glenmark Futures for target of Rs 1,000.

    • Anish Damania bullish on midcap pharma stocks

      Anish Damania, CEO of IDFC Securities is bullish on the midcap pharma names.

    • Super Six chart picks for today

      Gaurav Ratnaparkhi of Sharekhan is of the view that one may buy Larsen and Toubro (L&T) with a target of Rs 1435.

    • Buy HUL, prefer Lupin & Glenmark: Siddarth Bhamre

      Siddarth Bhamre of Angel Broking recommends buying HUL and prefers Lupin and Glenmark Pharma.

    • Bullish on pharma, auto, auto ancillaries space: SP Tulsian

      SP Tulsian of sptulsian.com has a bullish view on pharma, auto, auto ancillaries and the housing finance space.

    • Prefer Glenmark Pharma, Aurobindo Pharma: Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may prefer Glenmark Pharma and Aurobindo Pharma.

    • Look at Glenmark Pharma: Rajat Bose

      Rajat Bose of rajatkbose.com is of the view that one may look at Glenmark Pharma.

    • Pick Glenmark Pharma, says R Sreesankar

      R Sreesankar of Prabhudas Lilladher is of the view that one may pick Glenmark Pharma.

    • Buy Glenmark Pharma, enter Lupin on correction: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one can buy Glenmark Pharma and feels that one may enter Lupin on correction to about Rs 1850.

    • Prefer Glenmark Pharma, Syngene: Gaurang Shah

      According to Gaurang Shah of Geojit BNP Paribas Financial Services, one may prefer Glenmark Pharma and Syngene.

    • Prefer Glenmark Pharma, may test Rs 1120: Siddarth Bhamre

      Siddarth Bhamre of Angel Broking feels that Glenmark Pharma may test Rs 1120.

    • Short Glenmark, target Rs 970 in near term: Amit Harchekar

      Amit Harchekar of A Plus Analytics recommends shorting Glenmark Pharma with a target of Rs 970 in the near term.

    • Buy CESC, Ipca Labs, Glenmark Pharma, Rel Comm: Rajat Bose

      Rajat Bose of rajatkbose.com advises buying Glenmark Pharma, Ipca Labs and CESC.

    • Buy Tata Chemicals, Glenmark Pharma: Vishal Malkan

      Vishal Malkan of malkansview.com recommends buying Tata Chemicals and Glenmark Pharma.

    • Buy pharma stocks on corrections: Prakash Diwan

      Prakash Diwan of Altamount Capital Management is of the view that one may buy pharma stocks on corrections.

    • Buy Mercator, M&M Fin, Ceat, Glenmark: Gaurav Ratnaparkhi

      Gaurav Ratnaparkhi of Sharekhan recommends buying Mercator, Mahindra & Mahindra Financial Services, Ceat and Glenmark Pharma.

    • Jubilant Life may hit Rs 578, see upside in Glenmark: Bodke

      Ajay Bodke of Prabhudas Lilladher is of the view that Jubilant Life Sciences may test Rs 578 and expects upside in Glenmark Pharma.

    • Glenmark Pharma may test Rs 1090, says CA Rudramurthy BV

      CA Rudramurthy BV of Vachana Investments is of the view that Glenmark Pharma may test Rs 1090.

    • Super Six short term picks for October 1

      Manas Jaiswal of manasjaiswal.com advises buying Gail India with a target of Rs 325.

    • Pick Glenmark Pharma, Aurobindo Pharma: Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may pick Glenmark Pharma and Aurobindo Pharma from the pharma space.

    • Buy Reliance Industries, Wipro, Glenmark Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Reliance Industries, Wipro, Jubilant Life Sciences and Glenmark Pharma.

    • Buy Glenmark Pharma, Tata Comm; sell Adani Ports: LKP Sec

      Gaurav Bissa of LKP Securities recommends buying Glenmark Pharma and Tata Communications and advises selling Adani Ports.

    • Super Six chart picks for September 30

      Hemen Kapadia of KRChoksey Securities is of the view that one may buy Canara Bank with a target of Rs 287.

    • Bull's Eye: Voltas, HDIL, Ramco Ind, Rel Infra, Emami

      CA Rudramurthy BV of Vachana Investments advises buying Ramco Industries with a target of Rs 119.

    • Bull's Eye: Buy NCC, Ceat, Amara Raja, Tata Chem, Sintex

      Dharmesh Kant of India Nivesh Securities advises buying Canara Bank with a target of Rs 310.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347